SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Interleukin-1 (IL-1) plays a detrimental role in cerebral ischemia.
• IL-1 receptor antagonist (IL-1Ra) can mitigate these effects.
• Elevated interleukin-6 (IL-6) is linked to poor prognosis in ischemic stroke.

Purpose of the Study:

• To evaluate if subcutaneous IL-1Ra administration reduces peripheral inflammatory response in acute ischemic stroke.
• To assess the safety and tolerability of IL-1Ra in this patient population.

Main Methods:

• The SCIL-STROKE trial was a phase 2, randomized, placebo-controlled study.
• 80 patients received subcutaneous IL-1Ra or placebo within 5 hours of ischemic stroke onset.
• Plasma levels of IL-6 and C-reactive protein were measured, and 3-month outcomes were assessed using the modified Rankin Scale.

Main Results:

• IL-1Ra significantly decreased plasma IL-6 and C-reactive protein levels (P<0.001).
• The treatment was well-tolerated with no safety concerns.
• IL-1Ra did not significantly improve 3-month clinical outcomes (OR=0.67, P=0.34).

Conclusions:

• Subcutaneous IL-1Ra effectively reduces peripheral inflammatory markers in acute ischemic stroke.
• While safe and well-tolerated, IL-1Ra did not demonstrate improved clinical outcomes in this trial.
• Further research is needed to explore IL-1Ra efficacy and its interaction with thrombolysis.